Latest news
Latigo laces up for $247M IPO to fund non-opioid pain drug rival to Vertex’s Journavx - Fierce BiotechFierce Biotech · Tue, 04 Aug 2026 11:55:09 GMTVertex’s latest autoimmune TCE play involves $28M to AbCellera - Fierce BiotechFierce Biotech · Wed, 29 Jul 2026 12:20:42 GMTEli Lilly tops new biopharma ranking on launch success, development speed - Fierce BiotechFierce Biotech · Tue, 28 Jul 2026 17:00:12 GMT